NEK7 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2071980	0.51	16/20
SCHEMBL2072947	0.52	14/20
SCHEMBL2074912	0.51	14/20
SCHEMBL5123156	0.51	14/20
SCHEMBL2075874	0.54	13/20
SCHEMBL2075506	0.51	13/20
SCHEMBL2074654	0.58	12/20
SCHEMBL2074511	0.53	12/20
SCHEMBL3816347	0.53	12/20
SCHEMBL2072187	0.53	12/20
SCHEMBL2073071	0.53	12/20
SCHEMBL2074983	0.53	12/20
SCHEMBL2072763	0.51	12/20
SCHEMBL2074953	0.51	12/20
SCHEMBL1939985	0.51	12/20
SCHEMBL2071744	0.51	12/20
SCHEMBL2071764	0.51	12/20
SCHEMBL2076003	0.51	12/20
SCHEMBL3815379	0.49	12/20
SCHEMBL3815384	0.49	12/20

Clinical trials — most relevant to NEK7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers	PHASE1/PHASE2	RECRUITING
A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy	PHASE1	COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy	PHASE1	RECRUITING
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer	PHASE1	ACTIVE_NOT_RECRUITING
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
The Roles of Neutrophil Elastase in Lung Cancer	nan	UNKNOWN
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma	nan	COMPLETED
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib	nan	COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Molecular Analysis of Thoracic Malignancies	nan	ENROLLING_BY_INVITATION
Genetics of Neonatal Encephalopathy and Related Disorders	nan	RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Novel Biomarkers in Inflammatory Bowel Disease	nan	COMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NEK7 binder may also engage these)

Protein	Name	Similarity
Q9ES74	—	1.000	Q9ES74 →
D3ZBE5	—	1.000	D3ZBE5 →
G5EFM9	—	0.993	G5EFM9 →
P59895	—	0.991	P59895 →
A2BD05	—	0.990	A2BD05 →
NEK6	Serine/threonine-protein kinase Nek6	0.987	landscape →
Q9ES70	—	0.983	Q9ES70 →
P70236	—	0.977	P70236 →
Q5E9X2	—	0.976	Q5E9X2 →
MAP2K6	Dual specificity mitogen-activated protein kinase kinase 6	0.974	landscape →
Q9DGE0	—	0.971	Q9DGE0 →
B0XR80	—	0.971	B0XR80 →
Q0D0P5	—	0.971	Q0D0P5 →
Q0U4L8	—	0.971	Q0U4L8 →
A0A5B9GBF0	—	0.970	A0A5B9GBF0 →
Q52PH6	—	0.970	Q52PH6 →
A1CPG7	—	0.970	A1CPG7 →
O09110	—	0.969	O09110 →
A2QRF6	—	0.969	A2QRF6 →
MAP2K3	Dual specificity mitogen-activated protein kinase kinase 3	0.969	landscape →
Q8NJT7	—	0.969	Q8NJT7 →
A1D2C9	—	0.969	A1D2C9 →
Q6PWX2	—	0.969	Q6PWX2 →
Q4WSF6	—	0.969	Q4WSF6 →
G1XJZ4	—	0.968	G1XJZ4 →
Q2WGK3	—	0.968	Q2WGK3 →
Q4W6D3	—	0.968	Q4W6D3 →
Q6XKY3	—	0.968	Q6XKY3 →
A1IVT7	—	0.968	A1IVT7 →
Q2H332	—	0.967	Q2H332 →